• Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes
  • New data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfaction
  • Exploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithms
  • Data from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetes